trending Market Intelligence /marketintelligence/en/news-insights/trending/7MeZapDF1f4Y0ZMFbIzVrA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Evofem's resubmitted nonhormonal contraceptive gel to be reviewed by US FDA

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Evofem's resubmitted nonhormonal contraceptive gel to be reviewed by US FDA

Evofem Biosciences Inc.'s resubmission for approval of nonhormonal contraceptive gel Amphora has been received by the U.S. Food and Drug Administration and given a decision date of May 25, 2020.

The San Diego-based company's second application for approval is based on phase 3 trial results that showed Amphora had an 86% efficacy rate in preventing pregnancy, Evofem said in a Dec. 18 press release.

The FDA had previously rejected Amphora in 2016 due to patient data issues.

Amphora is a gel intended to regulate vaginal pH and is also being tested to prevent sexually transmitted diseases, including gonorrhea and chlamydia.

Few new contraceptives have come to market, an issue that advisers to the FDA have pointed out. If approved, Amphora would join diaphragms, condoms and copper intrauterine devices as a nonhormonal contraceptive option for women.